The biopharmaceutical company Cleveland BioLabs is focused on developing drugs for oncology and tissue protection, with a proprietary platform of Toll-like immune receptor activators that has applications in the mitigation of radiation injury and immuno-oncology. Their lead product candidate, entolimod, is an immuno-stimulatory agent developed as a radiation countermeasure and immunotherapy for oncology and other indications. Cleveland BioLabs has nine product candidates in their pipeline, developed by their subsidiaries Incuron, LLC and Panacela Labs, Inc., that have the potential to treat cancer, prevent and treat acute radiation syndrome, and counteract the toxic effects of radio and chemotherapy for oncology patients.